Sandbox:Arzu: Difference between revisions
Jump to navigation
Jump to search
Arzu Kalayci (talk | contribs) No edit summary |
Arzu Kalayci (talk | contribs) No edit summary |
||
| Line 13: | Line 13: | ||
| I C || For patients in whom TAVR or high-risk surgical AVR is being considered, a heart valve team consisting of an integrated, multidisciplinary group of healthcare professionals with expertise in VHD, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery should collaborate to provide optimal patient care. || 2014 recommendation remains current. || | | I C || For patients in whom TAVR or high-risk surgical AVR is being considered, a heart valve team consisting of an integrated, multidisciplinary group of healthcare professionals with expertise in VHD, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery should collaborate to provide optimal patient care. || 2014 recommendation remains current. || | ||
|- | |- | ||
| I B-NR || Surgical AR is recommended for symptomatic patients with severe AS (Stage D) and asymptomatic patients with severe AS (Stage C) who meet an indication for AVR when surgical risk is low or intermediate. || | | I B-NR || Surgical AR is recommended for symptomatic patients with severe AS (Stage D) and asymptomatic patients with severe AS (Stage C) who meet an indication for AVR when surgical risk is low or intermediate. || MODIFIED: LOE updated from A to B-NR. Prior recommendations for intervention choice did not specify patient symptoms. The patient population recommended for surgical AVR encompasses both symptomatic and asymptomatic patients who meet an indication for AVR with low-to-intermediate surgical risk. This is opposed to the patient population recommended for TAVR, in whom symptoms are required to be present. Thus, all recommendations for type of intervention now specify the symptomatic status of the patient. || | ||
|} | |} | ||
Revision as of 13:22, 20 October 2017
|
Aortic Stenosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty |
|
Transcatheter Aortic Valve Replacement (TAVR) |
|
Case Studies |
|
Sandbox:Arzu On the Web |
|
American Roentgen Ray Society Images of Sandbox:Arzu |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Associate Editor(s)-in-Chief: Arzu Kalayci, M.D. [2]
Overview
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Aortic Stenosis
Choice of Intervention
| COR LOE | RECOMMENDATION | COMMENT/RATIONALE | |
| I C | For patients in whom TAVR or high-risk surgical AVR is being considered, a heart valve team consisting of an integrated, multidisciplinary group of healthcare professionals with expertise in VHD, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery should collaborate to provide optimal patient care. | 2014 recommendation remains current. | |
| I B-NR | Surgical AR is recommended for symptomatic patients with severe AS (Stage D) and asymptomatic patients with severe AS (Stage C) who meet an indication for AVR when surgical risk is low or intermediate. | MODIFIED: LOE updated from A to B-NR. Prior recommendations for intervention choice did not specify patient symptoms. The patient population recommended for surgical AVR encompasses both symptomatic and asymptomatic patients who meet an indication for AVR with low-to-intermediate surgical risk. This is opposed to the patient population recommended for TAVR, in whom symptoms are required to be present. Thus, all recommendations for type of intervention now specify the symptomatic status of the patient. |